Inferra AIResearch Tools

Inferra AI / Company / SOLV

Solventum

SOLV · Health Care

Last earnings Aug 5, 2026  ·  Next earnings Nov 5, 2026

Key results

EPSquarter

$0.51

earnings per share of $0.51 adjusted diluted

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

earnings per share of $1.69

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Free cash flowfull-year

$59 million

free cash flow of $59 million Our solid second quarter fiscal year 2025 results mark five consecutive quarters of positive sales volume growth since implementing our transformation strategy, said Bryan Hanson, chief executive officer of Solventum.

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

AI analysis

Q2 2025 · reported Aug 7, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

EPS · Q2 2025
$0.51
EX-99 · Aug 7, 2025
Free cash flow · Full year
$59M
EX-99 · Aug 7, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
EPS$0.51——

EX-99 · Aug 7, 2025

Guidance · company-stated

Direction: Raised

Revenue

“htm EX-99.1 Document Exhibit 99.1 Solventum Reports Second Quarter 2025 Financial Results Reported sales increased 3.9% organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share outlook to $5.80 to $5.95 ST.”

Revenue$450M

“Full-Year 2025 Guidance Solventum is updating its full year 2025 guidance to reflect underlying business performance and flexibility to navigate the dynamic macroeconomic environment as follows Increased organic sales growth range to +2.0% to +3.0% (+2.5% to +3.5% excluding 50 bps of SKU exit impact) from prior range of +1.5% to +2.5% Increased adjusted EPS range to $5.80 to $5.95 from prior range of $5.45 to $5.65 Free cash flow in the range of $450M to $550M no change Note Full year 2025 guidance includes the Purification Filtration segment.”

Company outlook — Raised

“Given the continued and underlying momentum in our business and markets, we have raised our full year 2025 guidance at the top and bottom line reflecting confidence in our strategy and execution.”

Classified from the release's primary full-year outlook statement.

Next earningsNov 5, 2026Verified from the company’s own announcement

Cash flow & capex

Free cash flowfull year$59M

Capital allocation

Long-Term Debt and Short-Term Borrowings 14 NOTE 10.

Supplemental Equity and Comprehensive Income Information Share Repurchase Program In November 2025, Solventum's Board of Directors approved a share repurchase program, which authorizes the Company to purchase up to $ 1 billion of the Company's outstanding common stock.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Solventum Q2 2025 — earnings per share of $0.51 adjusted diluted

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 Document Exhibit 99.1 Solventum Reports Second Quarter 2025 Financial Results Reported sales increased 3.9% organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share outlook to $5.80 to $5.95 ST.”

Revenue: “Full-Year 2025 Guidance Solventum is updating its full year 2025 guidance to reflect underlying business performance and flexibility to navigate the dynamic macroeconomic environment as follows Increased organic sales growth range to +2.0% to +3.0% (+2.5% to +3.5% excluding 50 bps of SKU exit impact) from prior range of +1.5% to +2.5% Increased adjusted EPS range to $5.80 to $5.95 from prior range of $5.45 to $5.65 Free cash flow in the range of $450M to $550M no change Note Full year 2025 guidance includes the Purification Filtration segment.”

Revenue — Raised (“increased”)
“htm EX-99.1 Document Exhibit 99.1 Solventum Reports Second Quarter 2025 Financial Results Reported sales increased 3.9% organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share outlook to $5.80 to $5.95 ST.”

Company outlook — Raised (“raised”)
“Given the continued and underlying momentum in our business and markets, we have raised our full year 2025 guidance at the top and bottom line reflecting confidence in our strategy and execution.”

Revenue — Raised (“Increased”)
“Full-Year 2025 Guidance Solventum is updating its full year 2025 guidance to reflect underlying business performance and flexibility to navigate the dynamic macroeconomic environment as follows Increased organic sales growth range to +2.0% to +3.0% (+2.5% to +3.5% excluding 50 bps of SKU exit impact) from prior range of +1.5% to +2.5% Increased adjusted EPS range to $5.80 to $5.95 from prior range of $5.45 to $5.65 Free cash flow in the range of $450M to $550M no change Note Full year 2025 guidance includes the Purification Filtration segment.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Long-Term Debt and Short-Term Borrowings 14 NOTE 10.

SEC original ↗Solventum — 10-Q Quarterly report10-QAug 5, 2026

Supplemental Equity and Comprehensive Income Information Share Repurchase Program In November 2025, Solventum's Board of Directors approved a share repurchase program, which authorizes the Company to purchase up to $ 1 billion of the Company's outstanding common stock.

SEC original ↗Solventum — 10-Q Quarterly report10-QAug 5, 2026

Under this program, the Company repurchased 3.9 million and 4.8 million shares of its common stock for total consideration of approximately $ 288 million and $ 355 million through open market repurchases during the three and six months ended June 30, 2026, respectively.

SEC original ↗Solventum — 10-Q Quarterly report10-QAug 5, 2026

There were no repurchases made under this program in 2025.

SEC original ↗Solventum — 10-Q Quarterly report10-QAug 5, 2026

Long-Term Debt and Short-Term Borrowings The c arrying value includes the impact of debt issuance costs.

SEC original ↗Solventum — 10-Q Quarterly report10-QAug 5, 2026

Other borrowings consist of term loans utilized in connection with the exit of certain transition agreements with 3M.

SEC original ↗Solventum — 10-Q Quarterly report10-QAug 5, 2026

Strategy & priorities

Operating cash flow of $169 million free cash flow of $59 million Our solid second quarter fiscal year 2025 results mark five consecutive quarters of positive sales volume growth since implementing our transformation strategy, said Bryan Hanson, chief executive officer of Solventum.

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Given the continued and underlying momentum in our business and markets, we have raised our full year 2025 guidance at the top and bottom line reflecting confidence in our strategy and execution.

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Risks & headwinds

Forward-Looking Statements This news release contains forward-looking information about Solventum s financial results and estimates and business prospects, including guidance for 2025, that contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties.

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients lives for the better while empowering healthcare professionals to perform at their best.

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Solventum defines adjusted operating income as operating income excluding the effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, and impacts related to the sale of the Purification and Filtration business.

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Solventum defines adjusted diluted earnings per share as net income excluding the after-tax effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, and impacts related to the sale of the Purification and Filtration business and legal entity restructuring costs.

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

(d) Consists of charges and recoveries related to certain litigation matters.

SEC original ↗Solventum — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Legal Proceedings 40 Item 1A.

SEC original ↗Solventum — 10-Q Quarterly report10-QAug 5, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

30 documents

Earnings releases

7 documents

Presentations

0 documents

No presentations for Solventum are held in this edition of the library.

Transcripts

0 documents

No transcripts for Solventum are held in this edition of the library.

Mentioned by

4 companies

Other tracked companies whose held documents mention Solventum by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.